Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Chinese accelerator GDCC gains Asian rights to Biscayne's BIS001ER for epilepsy

Executive Summary

Biscayne Neurotherapeutics Inc. (BNT) licensed Global Drug Development Centre (GDCC; an accelerator and Chinese affiliate of VC firm Quark Venture) exclusive rights in China, Taiwan, Hong Kong and Macau (including intellectual property in these territories) to BNT's anti-epileptic candidate BIS001ER.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register